Fulltext

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

Im SA 1 , Gennari A 2 , Park YH 3 , Kim JH 4 , Jiang ZF 5 , Gupta S 6 Show all authors , Fadjari TH 7 , Tamura K 8 , Mastura MY 9 , Abesamis-Tiambeng MLT 10 , Lim EH 11 , Lin CH 12 , Sookprasert A 13 , Parinyanitikul N 14 , Tseng LM 15 , Lee SC 16 , Caguioa P 17 , Singh M 18 , Naito Y 19 , Hukom RA 20 , Smruti BK 21 , Wang SS 22 , Kim SB 23 , Lee KH 24 , Ahn HK 25 , Peters S 26 , Kim TW 27 , Yoshino T 28 , Pentheroudakis G 29 , Curigliano G 30 , Harbeck N 31

Affiliations 

  • 1 Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea. Electronic address: moisa@snu.ac.kr
  • 2 Department of Translational Medicine, University Piemonte Orientale, Novara, Italy
  • 3 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  • 4 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
  • 5 Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
  • 6 Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India
  • 7 Department of Internal Medicine, Hasan Sadikin General Hospital, Bandung, Indonesia
  • 8 Department of Medical Oncology, Shimane University Hospital, Shimane, Japan
  • 9 Cancer Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 10 Section of Medical Oncology, Department of Internal Medicine, Cardinal Santos Cancer Center, San Juan, The Philippines
  • 11 Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
  • 12 Department of Medical Oncology, National Taiwan University Hospital, Cancer Center Branch, Taipei, Taiwan
  • 13 Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
  • 14 Medical Oncology Unit, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand
  • 15 Taipei-Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
  • 16 Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, Singapore
  • 17 The Cancer Institute of St Luke's Medical Center, National Capital Region, The Philippines; The Cancer Institute of the University of Santo Tomas Hospital, National Capital Region, The Philippines
  • 18 Department of Radiotherapy, Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; Department of Oncology, Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 19 Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan
  • 20 Department of Hematology and Medical Oncology, Dharmais Hospital (National Cancer Center), Jakarta, Indonesia
  • 21 Medical Oncology, Lilavati Hospital and Research Centre and Bombay Hospital Institute of Medical Sciences, Mumbai, India
  • 22 Cancer Center, Sun Yat-sen University, Guangzhou, China
  • 23 Department of Oncology, Asan Medical Centre, Seoul, Republic of Korea
  • 24 Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
  • 25 Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea
  • 26 Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
  • 27 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  • 28 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  • 29 ESMO, Lugano, Switzerland
  • 30 Istituto Europeo di Oncologia, IRCCS, Milan, Italy; Department of Oncology and Haematology, University of Milano, Milan, Italy
  • 31 Breast Center, Department of Obstetrics and Gynaecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany
ESMO Open, 2023 Jun;8(3):101541.
PMID: 37178669 DOI: 10.1016/j.esmoop.2023.101541

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications